Overview of Entromax

Property	Description
Active ingredient	Bacillus clausii (spores)
Form	Oral Suspension or Powder for Oral Solution
Pharmacological class	Probiotic, restoring intestinal flora
General purpose	Supports healthy digestive balance
Origin	Biological/Natural (spore-forming bacteria)

Entromax is a medicine classified as a probiotic, a preparation containing beneficial, living microorganisms intended to support and restore the natural balance of the intestinal flora. Unlike antibiotics, which target and kill bacteria, the primary action of Entromax is focused on contributing to the microbial environment of the gut.

What Type of Medicine is Entromax?

Entromax is a single-ingredient formulation. Its core component is the active ingredient Bacillus clausii, a specific strain of spore-forming bacteria of biological/natural origin. This strain is characterized by its ability to form spores, an attribute that allows for high resilience to gastric acid. This resilience ensures the active bacteria reach the intestines intact, where they can activate and colonize.

The product is often available over-the-counter (OTC) and is commercially differentiated by its stable, liquid-based forms: either an oral suspension in small vials or a powder for oral solution in sachets, both designed for oral administration. This liquid or powder format makes it an accessible option for diverse patient groups.

The General Purpose of Entromax

The general purpose of Entromax is to support and stabilize a healthy digestive system by addressing imbalances in the microbial community of the gut, known as dysbiosis. By helping to establish a robust population of beneficial flora, the Bacillus clausii contributes to maintaining the natural protective barrier of the intestine. The ability of Bacillus clausii to colonize the gut contributes to a positive environment for microflora restoration. This clinically recognized action helps the body re-establish the correct balance of good bacteria to support normal digestive health. Its function is focused on restoring normal gastrointestinal microflora.

Regulatory References

Probiotics: Usefulness and Safety | NCCIH (NIH)

What side effects are possible with Entromax?

Possible Side Effects and Safety Information

The safety profile for Entromax (Bacillus clausii spores) is primarily defined by its live, biological nature and is documented by regulatory agencies worldwide. The adverse reactions listed are classified based on System-Organ Class (SOC) and generally report an unknown frequency due to being based on voluntary post-marketing experience, meaning incidence cannot be accurately estimated from available data.

Documented Adverse Reactions

The officially listed adverse reactions are categorized within two main System-Organ Classes:

Skin and Subcutaneous Tissue Disorders: Includes manifestations of hypersensitivity reactions such as rash, urticaria (hives), and angioedema (swelling beneath the skin).
Infections and Infestations: This category includes the potential for bacteremia, septicemia, or sepsis, which are documented as serious adverse reactions.

Serious Adverse Reactions and Safety Constraints

The potential for bacteremia or sepsis is a documented serious adverse reaction, especially when the medicine is administered to individuals with severely weakened immune systems or to hospitalized preterm infants. Public health advisories caution against use in these highly vulnerable groups due to the risk of invasive disease caused by live microorganisms.

Safety-Related Restrictions

The medicine is contraindicated in individuals with a known hypersensitivity to the active substance or its excipients. Furthermore, the product is strictly for oral use only. This restriction is a critical safety limitation, as reports have documented severe anaphylactic reactions when the medicine was incorrectly administered by injection.

The regulatory safety summary structures the understanding of risk by defining these population constraints and limiting the route of administration, thereby managing the inherent risks associated with its live bacterial component.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for the active ingredient in Entromax confirms that no specific clinical signs or symptoms of overdose have been formally reported in clinical experience or post-marketing surveillance. This finding reflects the generally low acute toxicity profile of this biological preparation.

Overdose management is restricted to symptomatic and supportive treatment, as the official label states that no specific antidote is known to exist.

Life-Threatening Complications

Regulatory authorities have noted a specific, severe risk in vulnerable populations: the potential for bacteraemia, septicemia, or sepsis. This life-threatening complication is primarily documented in individuals who are immunocompromised or who are hospitalized due to a serious illness.

When Immediate Medical Help Is Required

Due to the severity of this documented complication, immediate medical attention must be sought if a user, especially one in a high-risk group, suspects any signs of a systemic infection, such as sudden, unexplained fever or other symptoms of serious illness. This requirement for urgent medical care is explicitly mandated by regulatory findings concerning the active ingredient's severe risk profile, where hospital monitoring may be required.

Therapeutic Uses of Entromax

What Entromax Treats: Main Uses and Benefits

The active ingredient in Entromax is relevant for managing symptoms related to systemic imbalance in the gastrointestinal tract and is applied when appropriate for conditions involving episodic or fluctuating manifestations, including general gastrointestinal distress, diarrhea (acute and chronic), and managing certain intestinal bacterial flora disorders.

Entromax is applied during phases when symptoms become more noticeable, and is commonly used when short-term symptomatic assistance is needed, such as during antimicrobial therapies like antibiotics. This application provides support that helps ease the overall symptom burden associated with these treatments. The medication is relevant for managing symptom clusters that may become intense or disruptive, and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Digestive Discomfort The medicine is commonly used to help manage symptoms like abdominal cramping and loose stools that are symptoms related to systemic imbalance.

Eligibility and Restrictions for Use

Who can and cannot use Entromax?

The eligibility profile for Entromax is defined by official regulatory documentation, establishing which populations are permitted to use the medicine and which are restricted or contraindicated.

Populations for whom use is contraindicated

Patients with a known hypersensitivity or allergy to the active substance (Bacillus clausii spores) or to any of the product excipients are contraindicated.

Age-Related Eligibility and Conditional Use

Use is established and permitted across a broad spectrum of age groups, including Adults, Children, and Infants. No specific restriction is documented for the older adult population.
The medicine is subject to conditional use in specific high-risk populations. This includes individuals who are immunocompromised or those who are hospitalized due to a serious illness. For these groups, official labeling requires that use must only proceed if the potential benefits are deemed to outweigh the potential risks.

Physiological Status Restrictions

For individuals who are pregnant or breastfeeding, use is conditional and requires a medical assessment to ensure the benefits to the mother outweigh any potential risks.
The medicine is strictly for oral use only; administration via injection or other non-oral routes is explicitly prohibited.

What should I know about interactions with other medicines?

The interaction profile for Entromax (Bacillus clausii) is highly specific and is defined by the official regulatory information for live microbial products. Unlike many small-molecule medicines, the regulatory labeling affirms the absence of documented pharmacokinetic interactions involving common metabolic pathways, such as CYP enzymes, or human drug transporters (e.g., P-gp). Consequently, Entromax is not documented to alter the plasma concentrations or clearance of co-administered medicines through these mechanisms.

The single primary interaction pattern officially documented is based on pharmacodynamic antagonism with Antimicrobial Agents, including antibiotics. This interaction stems from the risk that antimicrobial medicines may diminish the biological viability of the active Bacillus clausii spores, potentially reducing the intended effect of Entromax.

Due to this documented risk of spore inactivation, official regulatory information mandates a timing-based administration restriction. Entromax must not be administered simultaneously with any antimicrobial agent. Official documents specify that the administration of Entromax and the antimicrobial agent must be separated by at least three hours. The regulatory profile contains no specific restrictions or warnings regarding interactions with food, alcohol, or common herbal supplements.

Mechanism of Action

Entromax, containing Bacillus clausii spores, functions as a probiotic that targets the gastrointestinal lumen and the intestinal microbial community. The spores survive the gastric barrier and germinate within the intestinal environment. The resulting vegetative cells establish transient colonization.

B. clausii engages in competitive inhibition against other microorganisms for nutrient substrates and adhesion sites on the intestinal epithelium. It also exhibits antagonistic activity by secreting antimicrobial substances, including specific bacteriocins, which disrupt the cell membrane integrity and metabolic processes of target bacterial strains.

Intracellularly, B. clausii contributes to the production and upregulation of host immunoglobulin A (IgA) secretion by epithelial and immune cells, promoting a local mucosal immune response. Furthermore, it aids in the de novo synthesis of certain B vitamins within the gut lumen. The system-level physiological consequence is the modulation of the gut microbiome composition through pathogen displacement and the stabilization of the resident bacterial community, leading to the preservation of gut barrier function.

Dosage and Administration Information

How to Use Entromax: Official Administration Guidelines

The administration of Entromax, a preparation containing Bacillus clausii spores, follows specific procedural requirements. The medicine is strictly for oral use only and is explicitly prohibited from being injected or administered through any other route.

Dosing and Frequency

Population	Typical Daily Dosage	Scheduling
Adults	2 to 3 units (mini bottles or capsules) per day	Administered in divided doses at regular intervals
Children/Infants	1 to 2 units (mini bottles or capsules) per day	Administered in divided doses at regular intervals

These regimens establish a daily intake target that typically ranges from 4 to 6 billion CFU of Bacillus clausii spores for adults.

Preparation and Administration Protocol

For the oral suspension form, the unit dose vial must be shaken well before use. The contents of the vial can be consumed undiluted or mixed (diluted) with common beverages such as water, milk, or tea. Once the mini bottle is opened, the contents should be consumed within a short period to maintain product integrity.

Administration Context

Treatment duration is typically short-term, with protocols for acute use generally spanning 5 to 14 days. When Entromax is used during concurrent antibiotic therapy, the administration of the probiotic preparation is specifically scheduled to occur in the interval between one dose of antibiotic and the next. This sequencing is a key procedural requirement for its use in this context. The product is generally permitted for use during pregnancy and lactation.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Entromax

Evidence for the Use in Acute Diarrhea and Gastroenteritis

Clinical evaluation for acute diarrhea was studied for conditions associated with acute or disruptive episodes using Randomized Controlled Trials (RCTs) and systematic reviews. Research examined these effects in both Children (including infants) and Adults.

Studies monitored outcomes describing episodic or acute changes like diarrhea duration, stool frequency, and hospitalization time. Findings showed a difference in time to symptom resolution compared to control groups, and some data describe changes in co-occurring symptoms. However, high variability (heterogeneity) across trials means certainty remains low for some broad clinical guidelines, and research is ongoing.

Research on Use During Antibiotic Therapy (Antibiotic-Associated Diarrhea)

Entromax was evaluated in research exploring temporary physiological imbalance observed alongside antibiotic therapy. Studies examined the incidence rate of diarrhea in the treated population compared to control groups during and shortly after antibiotic courses. Trials describe patterns of a lower rate of diarrhea occurrence and a change in general gastrointestinal outcomes measured by specific metrics. The follow-up durations were limited, typically covering the antibiotic period. Comparative evidence is lacking in large-scale studies designed to directly compare Entromax against a wide variety of other probiotic strains.

Research in Special Populations and Specific Situations

Research was studied for use in children with persistent diarrhea, but these trials have sample sizes were modest and were limited to younger ages. For all groups, the current body of evidence contributes to understanding short-term changes. Comprehensive insight into long-term effects is not fully established, and follow-up durations were limited in most key studies.

What Research Gaps and Uncertainties Remain

Scientific reviewers highlight areas where evidence is limited. Key limitations include the inherent variability across clinical trials, which makes forming a single, strong conclusion difficult. The results apply only to the populations studied and reflect the specific conditions under which they were conducted.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Entromax (FAQ)

Q: Can Entromax cause long-term side effects?

Official regulatory documents indicate that the comprehensive insight into the long-term safety of this medicine is not fully established. The known safety profile, which lists documented adverse reactions, is primarily based on voluntary post-marketing experience.

Q: Can I take Entromax with a daily vitamin supplement?

Official regulatory information does not document specific restrictions or warnings regarding interactions between this medicine and common vitamin supplements. The primary interaction documented in regulatory labeling is with antimicrobial agents, not nutritional supplements.

Q: Is use of Entromax permitted for people over the age of 65?

Official eligibility documentation confirms that the use of this medicine is permitted across a broad range of age groups, including adults. No specific age-related restriction or special warning is documented for the older adult population.

Q: How long does the effect of one dose of Entromax last?

The active component of the medicine works by establishing a state known as transient colonization in the gut, meaning the effect is temporary. Official documents do not define the specific duration in hours or days for the effect of a single dose.

Q: Is Entromax a controlled substance?

This medicine is classified as a probiotic, containing a component of biological origin. Based on official governmental drug classifications, this medicine is not listed as a controlled substance.

Q: Can Entromax be cut in half or crushed?

The medicine is supplied as an oral suspension that is administered directly or mixed into a beverage. Official administration protocols do not contain instructions for cutting, crushing, or otherwise altering the preparation.

Q: Why is Entromax sometimes prescribed for an extended period?

While the standard protocols for acute use typically span a short-term duration, official research evidence has examined the use of the medicine for conditions such as persistent diarrhea, which may correspond to a longer treatment duration.

Q: Are there any known issues with Entromax during pregnancy or breastfeeding?

Official documentation indicates that use during pregnancy or breastfeeding is conditional. A determination must be made regarding whether the benefits are deemed to outweigh potential risks.

Q: What happens if I forget to take a dose of Entromax?

Official regulatory sources describe a procedure where, if a dose is forgotten, it may be taken as soon as it is remembered. However, if the time for the next scheduled dose is near, the forgotten dose should be skipped, and the regular dosing schedule resumed.

Q: Will Entromax interact with my birth control pills?

Official regulatory documentation confirms the absence of documented pharmacokinetic interactions. This type of interaction would typically alter the concentration of co-administered medicines, and there are no specific warnings regarding interactions with oral contraceptive medicines.

Q: Does Entromax affect my ability to drive or operate machinery?

Official regulatory labeling indicates that this medicine has no influence on the ability to drive or to operate machinery.

Q: Are there any known interactions between Entromax and herbal supplements?

Official regulatory information states that there are no specific restrictions or warnings documented regarding interactions between this medicine and common herbal supplements.

Q: Can Entromax cause mood swings or changes in behavior?

Official regulatory documents define the known adverse reaction profile for this medicine. Mood swings or changes in behavior are not included in the documented adverse reactions.

Q: Is there a risk of dependence or addiction with Entromax?

This medicine is classified as a probiotic. Official regulatory documents contain no warnings or statements regarding a risk of dependence or addiction with its use.

Q: What population groups are usually excluded from clinical studies of Entromax?

Official research documents highlight limitations in the populations studied. Regulatory advisories include specific constraints or warnings for highly vulnerable groups, such as those with severely weakened immune systems or hospitalized preterm infants.

Q: Does Entromax expire?

Like all medical products, this medicine is assigned a limited expiration period by the manufacturer and should be stored according to official instructions. Unused or expired products must be disposed of according to local pharmaceutical waste regulations.

Q: Are there special considerations for people with kidney disease using Entromax?

Kidney disease is not listed as a specific contraindication or a special safety consideration in official regulatory documentation for this medicine.

Q: Is it possible to be allergic to Entromax?

Official documentation states that the medicine is contraindicated in individuals with a known hypersensitivity or allergy to the active substance or any of its components.

Q: What is the chance of getting a severe side effect from Entromax?

The serious adverse reactions listed, such as bacteremia or sepsis, are based on voluntary post-marketing reports. Due to this reporting method, the official regulatory safety profile states that the incidence or frequency of these reactions is unknown and cannot be accurately estimated.

Q: Do any official drug agencies require special warnings for Entromax?

Public health advisories do include specific warnings regarding the use of this medicine in certain vulnerable groups. These warnings are based on the documented risks associated with live microorganisms.

Q: What should I tell my doctor about before starting Entromax?

Official documentation requires attention to existing conditions before starting the medicine. Key considerations include a known hypersensitivity to the components or the presence of a severely weakened immune system.

Q: Can I travel with Entromax?

The medicine is highly stable and does not require refrigeration. It must be stored at a temperature not exceeding 30 C and protected from direct sunlight, heat, and excessive moisture, which are the main requirements for traveling with the product.

Q: Does Entromax interact with common heart or blood pressure medications?

Official regulatory documentation affirms the absence of documented pharmacokinetic interactions that would typically alter the plasma concentrations or clearance of co-administered medicines, such as common heart or blood pressure treatments.

How should Entromax be stored and disposed of?

How to Store and Dispose of Entromax

Entromax (Bacillus clausii spores) requires specific handling to maintain the stability of its active ingredient, as defined by official labeling.

Storage Conditions

Entromax must be stored at a temperature not exceeding 30°C and be kept in a cool, dry place. It is mandatory to protect the medicine from direct sunlight, heat, and excessive moisture. The product is highly stable and does not require refrigeration; however, freezing must be avoided.

Storage Restriction	Requirement
Temperature	Do not exceed 30°C.
Vial Integrity	Consume contents immediately after opening (single-use).
Child Safety	Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Entromax must not be thrown away with general household rubbish or disposed of via wastewater (flushed down the toilet). Patients must consult a pharmacist for proper disposal, which ensures the medicine is discarded according to local pharmaceutical waste regulations.

Entromax